Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services

Br J Haematol. 2018 Sep;182(6):936-939. doi: 10.1111/bjh.14897. Epub 2017 Aug 18.

Authors

Rakesh Popat¹, Emma Dowling², Sufyan Achhala¹, Devanshi Pandit¹, Neil Rabin¹, Charalampia Kyriakou¹, Stephen Mackinnon¹, Kwee Yong¹, Ashutosh Wechalekar¹

Affiliations

¹ University College London Hospitals NHS Foundation Trust, London, UK.
² Harley Street at University College Hospital, London, UK.

PMID: 28832959
DOI: 10.1111/bjh.14897

No abstract available

Keywords: immunotherapy; monoclonal antibodies; myeloma; myeloma therapy.

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Female
Hospitalization
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Infusion Pumps
Injection Site Reaction
Male
Middle Aged
Multiple Myeloma / drug therapy*
Time Factors
United Kingdom

Substances

Antibodies, Monoclonal
daratumumab